Chemomab Therapeutics (CMMB) gains 5.2% stake holder in Touchstone Global
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. is reported to have a significant shareholder, Touchstone Global Investments Pty Ltd of Australia. Touchstone reports beneficial ownership of 377,814 American Depositary Shares (ADSs), each ADS representing 80 ordinary shares. This holding represents 5.2% of the outstanding ADSs of this class.
Touchstone reports sole voting power and sole dispositive power over all 377,814 ADSs, with no shared voting or dispositive power. The position is reported on a Schedule 13G, indicating a passive ownership filing status as of the reported date.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned ADSs: 377,814 ADSs
Ownership percentage: 5.2%
ADS to ordinary share ratio: 1 ADS = 80 ordinary shares
+2 more
5 metrics
Beneficially owned ADSs
377,814 ADSs
ADSs of Chemomab Therapeutics beneficially owned by Touchstone Global Investments
Ownership percentage
5.2%
Percent of Chemomab Therapeutics ADS class held by Touchstone Global Investments
ADS to ordinary share ratio
1 ADS = 80 ordinary shares
Each American Depositary Share represents 80 ordinary shares, no par value
Sole voting power
377,814 ADSs
ADSs over which Touchstone Global Investments has sole power to vote
Sole dispositive power
377,814 ADSs
ADSs over which Touchstone Global Investments has sole power to dispose
Key Terms
beneficially owned, Sole Voting Power, Sole Dispositive Power, American Depositary Shares, +1 more
5 terms
beneficially owned financial
"Amount beneficially owned: 377814 ADSs"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole Voting Power financial
"Sole Voting Power 377,814.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power financial
"Sole Dispositive Power 377,814.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13G regulatory
"form_type: "SCHEDULE 13G""
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
FAQ
What percentage of Chemomab Therapeutics (CMMB) does Touchstone Global Investments own?
Touchstone Global Investments reports beneficial ownership of 5.2% of Chemomab Therapeutics’ ADSs. This stake is disclosed on a Schedule 13G, indicating a passive ownership position based on current shareholdings.
How many Chemomab Therapeutics (CMMB) ADSs does Touchstone Global Investments hold?
Touchstone Global Investments reports holding 377,814 American Depositary Shares (ADSs) of Chemomab Therapeutics. Each ADS represents 80 ordinary shares, giving Touchstone voting and dispositive power over this ADS amount.
What dispositive power does Touchstone Global Investments report over Chemomab (CMMB) ADSs?
Touchstone Global Investments reports sole dispositive power over 377,814 ADSs of Chemomab Therapeutics and no shared dispositive power, indicating it alone can decide if and when to sell or transfer those ADSs.
Is the Chemomab (CMMB) ownership filing by Touchstone Global Investments a Schedule 13G or 13D?
The ownership is reported on a Schedule 13G. This form is typically used for passive holders that exceed the 5% threshold, rather than for investors seeking to influence control via a Schedule 13D.
AI-generated analysis. How Rhea-AI works. Not financial advice.